Source comparison
Dosing Protocols for Central Versus Peripheral Effects
Kisspeptin's dual mechanism. Peripheral gonadotropin release and central limbic activation. Creates a dosing bifurcation that determines research outcomes. Peripheral effects (LH surge, testosterone elevation, ovulation triggering) respond to lower doses admin
This comparison does not assign a generated winner or score.
- Kisspeptin's dual mechanism. Peripheral gonadotropin release and central limbic activation. Creates a dosing bifurcation that determines research outcomes. Peripheral effects (LH surge, testosterone elevation, ovulation triggering) respond to lower doses administered via any route because KISS1R receptors in the anterior pituitary are accessible to circulating peptide. Central effects (sexual arousal, limbic activity, reward pathway modulation) require higher CNS concentrations that only IV bolus or continuous infusion can achieve reliably.
- The landmark Imperial College study used 1 nmol/kg IV kisspeptin-10 to demonstrate increased fMRI activity in the posterior cingulate cortex and thalamus during exposure to sexual imagery. Brain regions associated with sexual arousal and reward processing. Participants reported subjective increases in sexual desire within 30–45 minutes post-administration. A follow-up dose-escalation study tested 0.5, 1.0, 2.0, and 4.0 nmol/kg IV and found dose-dependent increases in limbic activation up to 2.0 nmol/kg, with no additional benefit at 4.0 nmol/kg. Suggesting a central saturation threshold around 2.0 nmol/kg for acute libido enhancement.
- Subcutaneous protocols targeting libido use significantly higher absolute doses to compensate for reduced bioavailability. Research published in Reproductive Biology and Endocrinology tested 10, 25, and 50 mcg subcutaneous kisspeptin-10 in men with hypogonadotropic hypogonadism and found that 25 mcg produced LH elevation comparable to 1 nmol/kg IV, but subjective libido ratings did not increase above baseline. The peripheral gonadotropin effect occurred without corresponding central activation. This pattern has been replicated across multiple trials: subcutaneous kisspeptin drives reproductive axis stimulation but does not reliably enhance sexual desire unless doses exceed 50 mcg, at which point side effects (nausea, injection site reaction) become limiting.
- Continuous infusion represents a third administration strategy. A 2021 pilot study used 4 nmol/kg/hour IV infusion over 22.5 hours and demonstrated sustained LH pulsatility and elevated testosterone without the acute peaks seen with bolus dosing. Limbic activation was not assessed, but the sustained pharmacokinetic profile suggests potential for libido enhancement with lower peak concentrations. An approach that may reduce side effects while maintaining central activity.